Servier is an international pharmaceutical company governed by a nonprofit foundation, with its headquarters in France (Suresnes). With a strong international presence in 149 countries and a turnover of 4.152 billion euros in 2017, Servier employs 21,700 people worldwide. “We are committed to therapeutic progress to serve patient needs.” as the vocation and entirely independent, the Group reinvests 25 percent of its turnover (excluding generic drugs) in research and development and uses all of its profits for development.
Corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiovascular, immune-inflammatory and neuropsychiatric diseases, cancer and diabetes. Servier also offers eHealth solutions beyond drug development.
Servier has a strong commitment to China. In 1979, Server became one of the first foreign companies to establish branch in China. Today, Servier has more than 2000 employees in China, and we have produced and promoted 7 medicaments, 14 different dosage forms in Mainland China in diabetes, hypertension and coronary artery disease therapeutic areas for the benefit of the Chinese healthcare professionals and their patients. We are committed to therapeutic progress to serve patient needs. Created in 2001, Servier (Beijing) Pharmaceutical Research & Development Co.,Ltd is to conduct clinical trials on drugs in development, both as part of international clinical trials and for specific Chinese registration needs. It is dedicated to the development of innovative medicines for China in different therapeutic areas such as cardiovascular, metabolism, rheumatology, neuropsychiatry and oncology.